Long‐term efficacy and safety of erenumab in migraine prevention: results from a 5‐year, open‐label treatment phase of a randomized clinical trial
M Ashina, PJ Goadsby, U Reuter… - European journal of …, 2021 - Wiley Online Library
Background and purpose Although erenumab has demonstrated significant reduction in
migraine frequency and improved quality of life in studies lasting 3 to 12 months, little is …
migraine frequency and improved quality of life in studies lasting 3 to 12 months, little is …
Long-term efficacy and safety of erenumab in migraine prevention: Results from a 5-year, open-label treatment phase of a randomized clinical trial
M Ashina, PJ Goadsby, U Reuter, S Silberstein… - 2021 - pubmed.ncbi.nlm.nih.gov
Background and purpose Although erenumab has demonstrated significant reduction in
migraine frequency and improved quality of life in studies lasting 3 to 12 months, little is …
migraine frequency and improved quality of life in studies lasting 3 to 12 months, little is …
Long-term efficacy and safety of erenumab in migraine prevention: Results from a 5-year, open-label treatment phase of a randomized clinical trial.
M Ashina, PJ Goadsby, U Reuter… - European Journal of …, 2021 - europepmc.org
Background and purpose Although erenumab has demonstrated significant reduction in
migraine frequency and improved quality of life in studies lasting 3 to 12 months, little is …
migraine frequency and improved quality of life in studies lasting 3 to 12 months, little is …
[HTML][HTML] Long‐term efficacy and safety of erenumab in migraine prevention: Results from a 5‐year, open‐label treatment phase of a randomized clinical trial
M Ashina, PJ Goadsby, U Reuter… - European Journal of …, 2021 - ncbi.nlm.nih.gov
Background and purpose Although erenumab has demonstrated significant reduction in
migraine frequency and improved quality of life in studies lasting 3 to 12 months, little is …
migraine frequency and improved quality of life in studies lasting 3 to 12 months, little is …
Long-term efficacy and safety of erenumab in migraine prevention: Results from a 5-year, open-label treatment phase of a randomized clinical trial
M Ashina, PJ Goadsby, U Reuter… - European Journal of …, 2021 - research.regionh.dk
BACKGROUND AND PURPOSE: Although erenumab has demonstrated significant
reduction in migraine frequency and improved quality of life in studies lasting 3 to 12 …
reduction in migraine frequency and improved quality of life in studies lasting 3 to 12 …
Long-term efficacy and safety of erenumab in migraine prevention: Results from a 5-year, open-label treatment phase of a randomized clinical trial
M Ashina, PJ Goadsby, U Reuter… - European Journal …, 2021 - mayoclinic.elsevierpure.com
Background and purpose: Although erenumab has demonstrated significant reduction in
migraine frequency and improved quality of life in studies lasting 3 to 12 months, little is …
migraine frequency and improved quality of life in studies lasting 3 to 12 months, little is …
Long-term efficacy and safety of erenumab in migraine prevention: Results from a 5-year, open-label treatment phase of a randomized clinical trial
M Ashina, PJ Goadsby, U Reuter… - European Journal of …, 2021 - kclpure.kcl.ac.uk
Background and purpose: Although erenumab has demonstrated significant reduction in
migraine frequency and improved quality of life in studies lasting 3 to 12 months, little is …
migraine frequency and improved quality of life in studies lasting 3 to 12 months, little is …